{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:44:03Z","timestamp":1791308643845,"version":"4.3.1"},"reference-count":69,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>High-dose methotrexate (HDMTX) therapy is a cornerstone in treating pediatric and adult cancers, namely, acute lymphoblastic leukemia, non-Hodgkin lymphoma, and osteosarcoma, due to its capability to penetrate the blood\u2013brain barrier. Despite its therapeutic benefits, HDMTX poses significant risks of delayed methotrexate elimination (DME) and associated toxicities such as acute kidney injury (AKI). These risks necessitate individualized dosing and preventive strategies, including hyperhydration, urine alkalinization, and leucovorin rescue.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To address these challenges, a modified Delphi method with two rounds was used to develop consensus statements to guide clinicians in mitigating HDMTX-associated toxicities and optimizing management strategies. A panel of 13 experts from Saudi Arabia, United Arab Emirates (UAE), Kuwait, Oman, Jordan, and Egypt formulated 54 initial statements focusing on HDMTX regimens, risk factors, preventive care, and monitoring strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Consensus (\u226575%) was reached on 50 statements covering HDMTX regimens, preventive care, and toxicity management. Recommendations emphasized standardized methotrexate monitoring intervals, structured risk assessment for DME and AKI, supportive care measures (hyperhydration, urine alkalinization), pharmacokinetically adjusted leucovorin rescue, and the role of glucarpidase in severe toxicity or AKI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This consensus provides concrete clinical strategies for the safe and effective use of HDMTX, including structured risk stratification for DME, standardized monitoring intervals, pharmacokinetically guided leucovorin adjustments, and early glucarpidase intervention in patients with AKI or severe toxicity. These recommendations are particularly relevant for optimizing HDMTX administration in regions with limited access to advanced interventions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1660937","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:29:19Z","timestamp":1762406959000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Consensus on managing delayed methotrexate elimination in high-dose therapy: insights from the Middle East"],"prefix":"10.3389","volume":"15","author":[{"given":"Mubarak","family":"Al Manasour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Absi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Faisal","family":"Khanani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayane","family":"Mheidly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elsaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walid","family":"Ballourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murtadha","family":"Al-Khabori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Al Zain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nisreen","family":"Khalifa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawad","family":"Rihani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Wali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1186\/s12885-021-08443-x","article-title":"Evaluation of body-surface-area adjusted dosing of high-dose methotrexate by population pharmacokinetics in a large cohort of cancer patients","volume":"21","author":"Arshad","year":"2021","journal-title":"BMC Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1080\/08880018.2023.2271013","article-title":"Access to methotrexate monitoring in Latin America: a multicountry survey of supportive care capacity","volume":"41","author":"Villanueva","year":"2024","journal-title":"Pediatr Hematol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00432-024-05945-6","article-title":"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment","volume":"150","author":"Bielack","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2023.10.005","article-title":"Outpatient administration of high-dose methotrexate in adults without drug monitoring\u2013a case-control study of risk factors for acute kidney injury","volume":"46","author":"Alves","year":"2024","journal-title":"Hematol Transfus Cell Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1507547","article-title":"Acute methotrexate-induced crystal nephropathy","volume":"373","author":"Garneau","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1749","article-title":"A Delphi study to determine the epidemiology and clinical management of patients treated with HDMTX who develop methotrexate (MTX) delayed elimination in France, Germany, Italy, and the UK","volume":"7","author":"Bielack","year":"2024","journal-title":"Health Sci Rep"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1280587","article-title":"Factors influencing delayed clearance of high dose methotrexate (HDMTX) in pediatric, adolescent, and young adult oncology patients","volume":"13","author":"Mosleh","year":"2023","journal-title":"Front Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13603","article-title":"Standardized supportive care documentation improves safety of high-dose methotrexate treatment","volume":"26","author":"Alsdorf","year":"2021","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220946464","article-title":"A second administration of glucarpidase in a different cycle of high-dose methotrexate: is it safe and effective in adults","volume":"27","author":"Domingo-Gonz\u00e1lez","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B11","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"B12","doi-asserted-by":"publisher","first-page":"152342","DOI":"10.1016\/j.seminoncol.2025.152342","article-title":"The interest of therapeutic and pharmacological drug monitoring of methotrexate: A systematic review","volume":"52","author":"Chellal","year":"2025","journal-title":"Semin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"908482","DOI":"10.3389\/fgene.2022.908482","article-title":"Global, regional, and national burden and trends of Down syndrome from 1990 to 2019","volume":"13","author":"Chen","year":"2022","journal-title":"Fron Genet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1182\/blood-2024-211870","article-title":"Understanding the associations between high-dose methotrexate pharmacokinetics and the risk of adverse events in children and adolescents with down syndrome associated high-risk acute lymphoblastic leukemia","volume":"144","author":"Westmoreland","year":"2024","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.15134","article-title":"Medication therapy of high-dose methotrexate: an evidence-based practice guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society","volume":"88","author":"Song","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"B16","unstructured":"Levels of evidence\n          \n          \n          \n          2009"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002","article-title":"Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies","volume":"67","author":"Diamond","year":"2014","journal-title":"J Clin Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.11.012","article-title":"High-dose methotrexate with leucovorin rescue: for monumentally severe CNS inflammatory syndromes","volume":"372","author":"Beh","year":"2017","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-021-04248-8","article-title":"A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma","volume":"87","author":"Fox","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30214-5","article-title":"Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial","volume":"17","author":"Marina","year":"2016","journal-title":"Lancet Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4999-24","article-title":"Delayed methotrexate elimination following high-dose methotrexate prophylaxis in high-risk diffuse large b-cell lymphoma","volume":"64","author":"Akimoto","year":"2025","journal-title":"Int Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16866","article-title":"The prevention of central nervous system relapse in diffuse large B-cell lymphoma: a British Society for Haematology good practice paper","volume":"190","author":"McKay","year":"2020","journal-title":"Br J Haematol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1177\/10781552221079568","article-title":"Incidence and management of patients with methotrexate delayed elimination in the clinical practice: a Delphi study","volume":"29","author":"Gros","year":"2023","journal-title":"J Oncol Pharm Pract"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8674","article-title":"High-dose methotrexate in pediatric acute lymphoblastic leukemia: predictors of delayed clearance and the effect of increased hydration rate on methotrexate clearance","volume":"12","author":"Chen","year":"2020","journal-title":"Cureus"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1177\/2399369319827305","article-title":"High-flux hemodialysis versus glucarpidase for methotrexate-associated acute kidney injury: what\u2019s best","volume":"3","author":"Kitchlu","year":"2019","journal-title":"J Onco-Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s12288-019-01144-3","article-title":"Serum methotrexate level and side effects of high dose methotrexate infusion in pediatric patients with acute lymphoblastic leukaemia (ALL)","volume":"36","author":"Sajith","year":"2020","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.840780","article-title":"High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis","volume":"55","author":"May","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.29518","article-title":"Overview of methotrexate toxicity: a comprehensive literature review","volume":"14","author":"Hamed","year":"2022","journal-title":"Cureus"},{"key":"B29","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1182\/blood-2021-151081","article-title":"Comparison of severe toxicities following high dose methotrexate administration by demographics and over time in pediatric patients with acute lymphoblastic leukemia","volume":"138","author":"Miller","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.22541\/au.164866504.46536405\/v1","article-title":"The effect of the plasma methotrexate concentration during high-dose methotrexate therapy on prognosis of childhood acute lymphoblastic leukemia","author":"Liao","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-03071-w","article-title":"Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma","volume":"113","author":"Nakano","year":"2021","journal-title":"Int J Hematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.21037\/tp-23-615","article-title":"Factors influencing delayed high-dose methotrexate excretion and its correlation with adverse reactions after treatment in children with Malignant hematological tumors","volume":"13","author":"Yu","year":"2024","journal-title":"Transl Pediatr"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.224774","article-title":"Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen","volume":"105","author":"Kroll","year":"2020","journal-title":"Haematologica"},{"key":"B35","first-page":"1001","article-title":"High dose methotrexate in oncological practice: a review and update on recent trends in administration and management of toxicity","volume":"1","author":"Purkayastha","year":"2018","journal-title":"Cancer Clin J"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70351","article-title":"Clinical risk factors for high-dose methotrexate-induced oral mucositis following individualized dosing","volume":"13","author":"Hu","year":"2024","journal-title":"Cancer Med"},{"key":"B37","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s43046-022-00122-7","article-title":"Is hypoalbuminemia a risk factor for high-dose methotrexate toxicity in children with acute lymphoblastic leukemia","volume":"34","author":"Barakat","year":"2022","journal-title":"J Egypt Natl Canc Inst"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1159\/000499100","article-title":"Therapeutic outcomes and toxicity of high-dose methotrexate-based chemotherapy for elderly patients with primary central nervous system lymphoma: a report on six cases","volume":"142","author":"Tempaku","year":"2019","journal-title":"Acta Haematol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.334","article-title":"High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study)","volume":"31","author":"Fritsch","year":"2017","journal-title":"Leukemia"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.2147\/IJNRD.S487368","article-title":"Serum methotrexate level predicts acute kidney injury after high-dose methotrexate: a case report and single-center experience","volume":"17","author":"Yen","year":"2024","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S188786","article-title":"Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study","volume":"11","author":"Demiralp","year":"2019","journal-title":"Clinicoecon Outcomes Res"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1177\/1078155220915769","article-title":"Oral sodium bicarbonate protocol for high-dose methotrexate urine alkalinization: a pediatric experience","volume":"27","author":"Diachinsky","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract14060205","article-title":"The use of acetazolamide to prevent acute kidney injury in patients with cancer on high-dose methotrexate treatment: a retrospective pilot analysis","volume":"14","author":"Lin","year":"2024","journal-title":"Clin Pract"},{"key":"B45","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s00228-023-03491-7","article-title":"Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review","volume":"79","author":"Liang","year":"2023","journal-title":"Eur J Clin Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268565","article-title":"Methotrexate-related central neurotoxicity: clinical characteristics, risk factors and genome-wide association study in children treated for acute lymphoblastic leukemia","volume":"107","author":"Mateos","year":"2022","journal-title":"Haematologica"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31744","article-title":"What Is the expected clearance of methotrexate? a therapeutic drug monitoring reference guide for high-dose methotrexate use in pediatric Malignancies","volume":"72","author":"Taylor","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"100456","DOI":"10.1016\/j.phoj.2025.100456","article-title":"A study on the safety of administering high dose methotrexate with a single monitoring of serum level of methotrexate at 72 hours and correlating it with the toxicity","volume":"21","author":"Singh","year":"2025","journal-title":"Pediatr Hemat Oncol J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1957","article-title":"MTXPK.org: a clinical decision support tool evaluating high-dose methotrexate pharmacokinetics to inform post-infusion care and use of glucarpidase","volume":"108","author":"Taylor","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.912999","article-title":"Renal function and plasma methotrexate concentrations predict toxicities in adults receiving high-dose methotrexate","volume":"24","author":"Yang","year":"2018","journal-title":"Med Sci Monit"},{"key":"B51","doi-asserted-by":"publisher","first-page":"100649","DOI":"10.1016\/j.sbsr.2024.100649","article-title":"Clinical feasibility of a label-free SERS assay for therapeutic drug monitoring of methotrexate","volume":"44","author":"Dumont","year":"2024","journal-title":"Sens Bio-Sens Res"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08030621","article-title":"Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"17","author":"Ghannoum","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1179\/acb.2006.028","article-title":"Methotrexate should not be used for patients with end-stage kidney disease","volume":"61","author":"Boey","year":"2006","journal-title":"Acta Clin Belg"},{"key":"B54","first-page":"66","article-title":"High dose methotrexate and extended hours high-flux hemodialysis for the treatment of primary central nervous system lymphoma in a patient with end stage renal disease","volume":"2","author":"Mutsando","year":"2012","journal-title":"Am J Blood Res"},{"key":"B55","unstructured":"Alltogether protocol: HDMTX guidelines (version 2)\n          \n          \n            \n              Heldrup\n              J\n            \n            \n              Schmiegelow\n              K\n            \n          \n          \n          2023"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1846733","article-title":"Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients","volume":"62","author":"Medrano","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.799","article-title":"Use of glucarpidase (carboxypeptidase-G2) in pediatric cancer patients: 11-year experience of a tertiary center","volume":"4","author":"Vila","year":"2023","journal-title":"Ejhaem"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30506","article-title":"A pooled subgroup analysis of glucarpidase treatment in 86 pediatric, adolescent, and young adult patients receiving high-dose methotrexate therapy in open-label trials","volume":"70","author":"Janeway","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.01.006","article-title":"Fixed-dose glucarpidase for toxic methotrexate levels and acute kidney injury in adult lymphoma patients: case series","volume":"21","author":"Truong","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2147\/CEOR.S397154","article-title":"Glucarpidase for treating adults with delayed methotrexate elimination due to impaired renal function: an economic simulation analysis","volume":"15","author":"Kala","year":"2023","journal-title":"Clinicoecon Outcomes Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1182\/blood-2023-189432","article-title":"Clinical outcomes in patients with high-dose methotrexate toxicity treated with vs. without glucarpidase","volume":"142","author":"Gupta","year":"2023","journal-title":"Blood"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.10.004","article-title":"Late administration of glucarpidase in methotrexate intoxication: do we have more time than we thought","volume":"119","author":"Miceli","year":"2024","journal-title":"Eur J Intern Med"},{"key":"B64","unstructured":"Standard for antidote stocking in healthcare facilities\n          \n          UAE\n          \n          2024"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00623-4","article-title":"Essential medicines for childhood cancer in Europe: a pan-European, systematic analysis by SIOPE","volume":"23","author":"Otth","year":"2022","journal-title":"Lancet Oncol"},{"key":"B66","article-title":"NCCN guideline update outlines best practices with high-dose methotrexate, glucarpidase in patients with ALL\/B-cell lymphoma","author":"Doherty","year":"2023","journal-title":"Oncol Nurs News"},{"key":"B67","doi-asserted-by":"publisher","first-page":"100029","DOI":"10.1016\/j.ejcped.2023.100029","article-title":"European standard clinical practice recommendations for children and adolescents with primary and recurrent osteosarcoma","volume":"2","author":"van Ewijk","year":"2023","journal-title":"EJC Paediatr Oncol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"585","DOI":"10.3390\/pharmaceutics17050585","article-title":"Impact of pharmacogenetics on high-dose methotrexate toxicity in pediatric oncology","volume":"17","author":"Marangoni-Iglecias","year":"2025","journal-title":"Pharmaceutics"},{"key":"B69","doi-asserted-by":"publisher","first-page":"1561818","DOI":"10.3389\/fphar.2025.1561818","article-title":"Risk factors associated with high-dose methotrexate induced toxicities in primary central nervous system lymphoma","volume":"16","author":"Li","year":"2025","journal-title":"Fron Pharmacol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1660937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:29:58Z","timestamp":1762428598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1660937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":69,"alternative-id":["10.3389\/fonc.2025.1660937"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1660937","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1660937"}}